Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care

Contributed by: Business Wire

Logo

Tags

Health

Medical Devices

Other Health

General Health

Research

Science

Biotechnology

lymphatic drainage

More Like This

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

BLA for subcutaneous formulation of Leqembi® accepted in China

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

PR Newswire associated0

UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China